Pharmaceuticals, Biotechnology and Life Sciences
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.
Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.
First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia…
Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.
Actinium Pharmaceuticals has applied an Investigational New Drug for Actimab-A combined with CLAG-M, for Acute Myeloid Leukemia, to the USFDA.
CTI BioPharma is expecting $10 million milestone in February, 2018 from Teva, related to a milestone for U.S. Food and…
Israel’s largest drugmaker, and world’s renown generic drug’s leading producer Teva, through it’s USA outpost Teva Ltd, said that that…
Mylan and its partner, Aspen have announced the U.S. launch of Myleran (busulfan) Injection, 60 mg/10 mL (6 mg/mL) Single-dose…
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
US Food and Drug Administration (FDA) has approved Novartis’s Kymriah suspension for intravenous infusion, formerly CTL019, the first chimeric antigen…